High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
about
Adoptive immunotherapy for cancer: building on successBTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccinationDegeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humansThymic selection generates a large T cell pool recognizing a self-peptide in humansT cell responses against tumor associated antigens and prognosis in colorectal cancer patientsTo affinity and beyond: harnessing the T cell receptor for cancer immunotherapyHepatitis C virus immune escape via exploitation of a hole in the T cell repertoireStructures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell RecognitionGerm Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell ReceptorCrystal Structures of HLA-A*0201 Complexed with Melan-A/MART-1 26(27L)-35 Peptidomimetics Reveal Conformational Heterogeneity and Highlight Degeneracy of T Cell RecognitionTCRs Used in Cancer Gene Therapy Cross-React with MART-1/Melan-A Tumor Antigens via Distinct MechanismsHost type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cellsEvidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidityMHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer.Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization.In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes.Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapyAdministration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigenHuman naive and memory CD4+ T cell repertoires specific for naturally processed antigens analyzed using libraries of amplified T cells.Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapyNatural immunity to pluripotency antigen OCT4 in humans.A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.Patient immune response to tumors monitored using SCID mouse models.CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination.Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.Detection of antigen-specific cytotoxic T lymphocytes: significance for investigative dermatology.New methods for assessing T-cell responses.Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization.Protocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells.Tumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation.Autoimmune melanocyte destruction in vitiligo.Immunotherapy of melanoma.
P2860
Q24546258-7EC8BF40-F062-4280-8513-A658480CCA42Q24652965-FF24A5B7-845E-4A46-A1E3-D308E8585342Q24673373-7CBCCC57-712D-460A-8D73-DAEA8C28F7B9Q24675080-5193418E-DDF3-43C4-8FB8-D23749E7DDB7Q24796257-F45478C7-3662-4B86-846F-CB46D04F430BQ27008423-33251FDF-16EA-425F-B2E5-27D67D7F434CQ27489598-60E4BA50-71C7-424F-A909-6C4078E6D049Q27647534-F07B5812-D076-4291-8F60-A8E0FB09EC13Q27656470-CD26E020-892B-4079-8F8C-41BC4746C14FQ27664235-0976B87F-5014-42D8-B919-748B525A5072Q27671024-8CEBED4D-9841-4DDD-823A-44544D81B73FQ28248489-C96B289F-972B-4F42-AC25-AB6AE3D123E6Q28360452-0320681C-140B-46C6-B0B4-8F40F25209EEQ30303138-3A873B74-E37B-4531-9684-69797FFFA8AEQ30550855-D1520DA9-C148-4FA0-A770-3363455DC3FFQ33178945-6526E430-FA54-406B-B14B-F796800413EBQ33211563-AD02BE1A-76E9-4F8F-A2BE-923E79FC2A81Q33282703-CA6D0DEC-C5E4-4CA7-91E5-50BD05A6B79DQ33299427-BE1A0E12-5FCA-473E-AD0E-FEB451B9D111Q33322422-5A2B5A36-8FF9-4063-8F40-4C4AE7F47C07Q33476079-D70B5CA5-84A5-41B8-8A45-6B6A5473ED64Q33530146-14D42649-9324-4E40-9C32-876B7E5314F5Q33588711-E916CE44-E685-470F-A2EF-8F3305C32621Q33750205-D5EF7B7B-2E07-4BD5-8BF9-65BB46081476Q33772145-160C8E18-4706-4AB6-BF3E-0FB5ADAB6E8EQ33871399-6780AEC4-2CC5-4588-B0DA-C6443BB35220Q33911899-C53C2333-E555-47A8-BDCE-3C9F62665A58Q33928635-F78806E7-86E1-461B-AF1C-1CAAB6C95400Q33943139-852C0DDE-DCA2-402D-A584-631D62D58685Q33943153-38D45907-AA4A-4017-BAF3-4A75B819B097Q33943864-B062EBA5-FB57-4B79-ACFF-B51602148EE6Q34020057-75BD91F8-C561-48FD-99D7-E8010896E0CEQ34022532-D5F702E9-25B9-441F-951A-54D18DD2A51AQ34076691-2509DFBA-2284-4FC2-8886-69E120E726A1Q34162609-9FE7BE2A-32DD-4B8D-88B0-6A24A0F0A762Q34261705-ACFBE0D5-5DE8-462A-8985-65B76C039277Q34265381-89AAAEA5-120B-44A7-9B62-D7A23F7426F3Q34331357-EE7B8EB0-602C-4DB1-9084-18F65ACFD8C8Q34335855-28DC8DC4-0555-4483-8BFD-6EB731FBFF94Q34383950-AA354E19-B30E-4E17-9548-90F1632A5B29
P2860
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
High frequencies of naive Melan-A/MART-1-specific CD8
@nl
High frequencies of naive Mela ...... antigen (HLA)-A2 individuals.
@en
type
label
High frequencies of naive Melan-A/MART-1-specific CD8
@nl
High frequencies of naive Mela ...... antigen (HLA)-A2 individuals.
@en
prefLabel
High frequencies of naive Melan-A/MART-1-specific CD8
@nl
High frequencies of naive Mela ...... antigen (HLA)-A2 individuals.
@en
P2093
P2860
P356
P1476
High frequencies of naive Mela ...... antigen (HLA)-A2 individuals.
@en
P2093
D E Speiser
J C Cerottini
K Fleischhauer
M J Pittet
P R Dunbar
P2860
P304
P356
10.1084/JEM.190.5.705
P407
P577
1999-09-01T00:00:00Z